|
ActoGeniX expands its management team and appoints Anders Waas as VP business development
Ghent, February 4th, 2008 - ActoGeniX appoints Dr Anders Waas as its new Vice President Business Development. With this appointment ActoGeniX is further expanding its management team to support its strong growth and development as a leading biopharmaceutical company.
Anders Waas has over two decades of experience in the pharmaceutical, biotech and medical device industries. From 2004 to 2008, he was Vice President Business Development at CV Therapeutics in Palo Alto (US). Between 1992 and 2004 he held various senior management positions in product development, marketing and business development at Astra and AstraZeneca. These included: Director of Cardiovascular Global Licensing activities at AstraZeneca and Director of Strategic Planning and Business Development for cardiovascular, metabolic and gastrointestinal products at Astra. In this position he was responsible for the global strategic support of products such as Losec, Nexium, Toprol XL, Atacand, Exanta and for the overall R&D efforts in cardiovascular, metabolic and gastro-intestinal diseases. Anders was also active in the medical device industry as European Sales Leader and Medical Advisor at WL Gore & associates. Dr Anders Waas received his DDS (Dr Dental Surgery) from University of Umea, Sweden. Upon his appointment Dr Waas stated: “I am very pleased to join ActoGeniX, which I believe is a company with unique potential. The company has currently built an impressive portfolio of therapeutic products for a variety of diseases with high medical need, and has a lead program that will soon enter phase 2 clinical studies. This represents an enviable business development opportunity”. Dr Mark Vaeck, CEO of ActoGeniX, commented: “ We are delighted that Anders has accepted to join ActoGeniX. With his extensive business experience I am convinced he will make a significant contribution to building ActoGeniX into a major and commercially successful biopharmaceutical company”.
For further information please contact:
ActoGeniX
Dr Mark Vaeck, Chief Executive Officer - Phone +32 (0)9 2610600 - mark.vaeck@actogenix.com Dr Anders Waas, Vice President Business Development - Phone +32 (0)9 2610600 - anders.waas@actogenix.com About ActoGeniX
ActoGeniX is a biopharmaceutical company which focuses on the development and commercialization of ActoBiotics™, a novel class of biopharmaceuticals for the targeted treatment of severe gastrointestinal diseases, metabolic diseases, immune disorders and allergies. ActoBiotics™ can be orally administered and are designed to be safer and more effective than injectable biopharmaceuticals. ActoGeniX’s initial focus is on GI diseases and its first product for the treatment of Crohn’s disease and ulcerative colitis has already been successfully tested in a phase 1 clinical trial. ActoGeniX was founded in 2006 as a spin-off from VIB and Ghent University. The company is headquartered in Ghent (Belgium) and employs close to 40 employees, half of whom are PhD’s, MD’s, or PharmD’s. Within the first year after its inception, the company raised 20 million Euro through a Series A equity round from a consortium of leading life sciences investors such as GIMV, Biotech Fund Flanders, Baekeland Fund (Belgium), Life Sciences Partners, Aescap (The Netherlands) and Ventech (France). ActoGeniX has a strong and broad intellectual property position with a patent estate encompassing 16 distinct patent families. With broad patent claims already granted in major territories like the US and Europe, ActoGeniX is now in a unique position to successfully exploit the commercial potential of its promising new class of biopharmaceutical products. For more information see www.actogenix.com.
Publisher Contact Information:
ActoGeniX NV
+32 (0)9 2610600
mark.vaeck@actogenix.comCompany profile of ActoGeniX NV (acquired by Intrexon)
Past press releases of ActoGeniX NV (acquired by Intrexon).
| 
